Person: Fernández Arancibia, Mario
Loading...
Email Address
Birth Date
Research Projects
Organizational Units
Job Title
Last Name
Fernández Arancibia
First Name
Mario
Name
Mario Fernández Arancibia
1 results
¿Qué estás buscando?
Search Results
Now showing 1 - 1 of 1
Publication Bladderpreservationalternativesin non-metastaticmuscle-invasivebladder tumor:Asystematicreviewand meta-analysis(2025) Parrao, Diego; Lizana, Nemecio; Saavedra, Catalina; Fernandez, Valentina; Lindsay, Carolina; Larrañaga, Matıas; Fernández Arancibia, Mario; Bravo. JuanObjective: To systematically review the most recent scientific literature regarding modern strategies for organ preservation in the treatment of non-metastatic muscle-invasive bladder cancer. Methods: Literature search was made using PubMed, Google Scholar, EMBASE, Wiley Library, and ClinicalTrials.gov following the recommendations of the Preferred Reporting Items for Systematic reviews and Meta-Analyses statement. The primary outcome was 5-year overall survival rate, which was addressed by a systematic review and meta-analysis. The risk of bias and quality of evidence were assessed according to the Cochrane Collaboration and the Grading of Recommendations, Assessment, Development and Evaluation system. Results: The evidence is consistent in showing that 5-year survival of trimodality therapy is similar to radical cystectomy in selected patients, ranging between 29% and 73%. Patients undergoing bladder-sparing therapy were found to have better outcomes in terms of quality of life and sociability than those undergoing radical cystectomy. Immunotherapy is establishing itself as a strategy for organ-preservation treatment, showing complete response rates between 42% and 100%. However, most of these results have been obtained from ongoing clinical trials. Furthermore, there are still no studies comparing the efficacy among the different available therapies. Conclusion: Although radical cystectomy remains the gold standard treatment for muscle-invasive bladder cancer, its significant morbidity has prompted the exploration of alternative therapies. In this context, bladder preservation therapies, though supported by limited literature, emerge as a potential alternative that could offer comparable oncological outcomes in selected patients.